Centralised Procedure (CP)
A centralised procedure is one where an agency reviews and approves applications from all member states at once. Certain drugs, such as biotechnology, HIV, cancer, and diabetes, must be reviewed by the European Medicines Agency (EMA).
More information about Centralised Procedure (CP)
Product,centralised procedure,procedure,medicines,medicinal products,companies,patients,decision,time,active substances,submissions,process,diseases,opinion,authorization,period,route,risk,healthcare professionals,timeline,immune dysfunctions,scientific assessment.
Centralized procedure,class of medicines,Authorisation of medicines,human medicines,orphan medicines,Committee for Medicinal Products for Human Use,agency,studies,documents,reports,viral diseases.
Positive opinion,biotechnological processes,level,European Union,immune deficiency syndrome,neurodegenerative disorders,marketing authorisation,centralised authorisation procedure,decentralised procedure,decentralized procedure,mutual recognition procedure,referral procedure,types of product,pre – submission.
Application process,Committee for Medicinal,marketing authorizations,languages,assessment reports,auto-immune diseases,laboratory to patient,variations,processes,package leaflet,chemical entities,letter of intent,marketing-authorisation holder,pharmaceutical sector,marketing authorisation applications,centralised marketing authorisation,marketing authorisation holder,single marketing authorisation,formal approval,single application,advanced therapy,therapy medicinal,regulatory pathway,mammalian cells,centralised marketing authorisation procedure,National authorisation procedures,national procedure,procedure manager,appeals procedure,application procedure,detailed procedure,empowerment procedure,European Centralized Procedure,European procedure,European Union-wide procedure,evaluation procedure,safety of medicines,complex medicines,innovative medicines,medicine development,access to medicines,advanced-therapy medicines,approval of medicines,generic medicines,product characteristics,innovative products,Applicants of products,biotechnology products,consistency across products,generic products,commission decision,binding decision,class waiver decision,decision for renewals,decision letter,decision step,draft decision,submission package,timing of submissions,actual submission,Dedicated submission,delay in submission may,documents for submission,linguistic review process,approval process,regulatory approval process,assessment process,entire process,essential process,Committee,22-day standing committee consultation,committee responsible,competent committee,dedicated committee,marketing authorization holder,authorization pathways,community authorization,EU-wide marketing authorization,European Medicines Agency,| European Medicines Agency,agency at Day,agency validation,key time,additional time,Approximate Course Time,clock-stock times,repeat-dose toxicity studies,2- and 4-week repeat-dose studies,clinical studies,Collaborative study,official languages,language files,language PIs,linguistic review period,2-week period,five-year period,clean documents,clean PDF documents,correct document properties,Periodic safety update reports,draft assessment report,cancer diabetes neurodegenerative diseases,European authorisation route,authorisation route,centralised route,lab to patient,favourable opinion,5-digit company number,applicant company,categories of variations,examination of variations,carcinogenic risk,effectiveness of risk minimisation,healthcare payers,documents for healthcare providers,interactive timeline,67-day timeline,biotechnology processes,national level,European level.